Format

Send to

Choose Destination
Euro Surveill. 2019 Feb;24(8). doi: 10.2807/1560-7917.ES.2019.24.1900121.

Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.

Author information

1
These authors contributed equally to the study and manuscript writing.
2
EpiConcept, Paris, France.
3
Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
4
National Epidemiology Centre, Institute of Health Carlos III, Madrid, Spain; CIBER de EpidemiologĂ­a y Salud PĂșblica (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
5
Public Health England, London, United Kingdom.
6
National Centre for Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Institute of Health Carlos III, Madrid, Spain.
7
Department of Virus and Microbiological Special diagnostics, National Influenza Center, Statens Serum Institut, Copenhagen, Denmark.
8
European Influenza Vaccine Effectiveness (IVE) group members are listed at the end of the article.

Abstract

Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.

KEYWORDS:

Europe; influenza; multicentre study; test-negative design; vaccination; vaccine effectiveness; vaccines and immunisation

Free full text

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center